HC Wainwright Has Bearish Forecast for MIST FY2028 Earnings

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) – Investment analysts at HC Wainwright dropped their FY2028 earnings per share estimates for Milestone Pharmaceuticals in a research note issued to investors on Monday, March 17th. HC Wainwright analyst P. Trucchio now anticipates that the company will earn $0.43 per share for the year, down from their previous forecast of $0.46. HC Wainwright has a “Buy” rating and a $25.00 price objective on the stock. The consensus estimate for Milestone Pharmaceuticals’ current full-year earnings is ($0.62) per share. HC Wainwright also issued estimates for Milestone Pharmaceuticals’ FY2029 earnings at $1.81 EPS.

Milestone Pharmaceuticals Trading Down 16.4 %

Shares of MIST opened at $1.99 on Wednesday. Milestone Pharmaceuticals has a fifty-two week low of $1.12 and a fifty-two week high of $2.75. The firm has a market cap of $106.12 million, a price-to-earnings ratio of -2.46 and a beta of 1.83. The firm has a 50 day moving average price of $2.02 and a 200-day moving average price of $1.81. The company has a debt-to-equity ratio of 2.18, a quick ratio of 15.40 and a current ratio of 15.40.

Institutional Trading of Milestone Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in MIST. Atria Investments Inc increased its holdings in shares of Milestone Pharmaceuticals by 44.4% in the third quarter. Atria Investments Inc now owns 40,421 shares of the company’s stock worth $61,000 after buying an additional 12,430 shares during the period. PVG Asset Management Corp bought a new position in Milestone Pharmaceuticals during the 3rd quarter worth approximately $46,000. Toronto Dominion Bank purchased a new position in Milestone Pharmaceuticals in the 4th quarter worth approximately $1,770,000. Cubist Systematic Strategies LLC bought a new stake in Milestone Pharmaceuticals in the fourth quarter valued at approximately $73,000. Finally, Boxer Capital Management LLC purchased a new stake in shares of Milestone Pharmaceuticals during the fourth quarter valued at approximately $729,000. 86.18% of the stock is owned by institutional investors.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.